Who Exports Lenalidomide from India — 237 Suppliers Behind a $883.1M Market

Hyderabad, often referred to as the "Bulk Drug Capital of India," is a pivotal hub for pharmaceutical manufacturing. The city hosts Genome Valley, India's first biotech cluster, and is home to over 800 pharmaceutical companies, including major players like Dr. Reddy’s Laboratories and Aurobindo Pharma. This concentration of industry is supported by advanced R&D infrastructure and a skilled talent pool from institutions such as the National Institute of Pharmaceutical Education and Research (NIPER) and the Indian Institute of Chemical Technology (IICT).

Hyderabad's specialization in Active Pharmaceutical Ingredients (APIs), vaccines, biologics, and biosimilars positions it as a key player in the production of complex drugs like Lenalidomide. The Telangana government's initiative to develop "Pharma City," poised to be the world's largest integrated pharma cluster, further underscores the region's commitment to pharmaceutical excellence.

The Ahmedabad-Vadodara corridor in Gujarat is renowned for its robust pharmaceutical manufacturing capabilities. Gujarat contributes nearly 28% of India's pharmaceutical production and is home to a mature pharma ecosystem. Major companies such as Zydus Lifesciences, Intas Pharmaceuticals, Torrent Pharmaceuticals, and Cadila Pharmaceuticals are headquartered here.

This region's strong support infrastructure, including ports, roads, power, and water, facilitates efficient production and export of pharmaceutical formulations. The presence of these industry leaders indicates a significant capacity for manufacturing and exporting drugs like Lenalidomide.

The Mumbai-Thane-Raigad belt in Maharashtra serves as a critical export gateway for India's pharmaceutical products. Maharashtra leads the country with the highest number of pharmaceutical clusters, totaling 40 as of February 2023. This region's strategic location and well-developed infrastructure make it a hub for pharmaceutical exports.

Sun Pharmaceutical Industries Limited, headquartered in Mumbai, is the largest pharmaceutical company in India and the fourth-largest specialty generic pharmaceutical company globally. With manufacturing facilities across 43 locations worldwide, including significant operations in Maharashtra, Sun Pharma's substantial export activities, particularly to the United States, highlight the region's role in the global pharmaceutical supply chain.

The Baddi-Nalagarh region in Himachal Pradesh has emerged as a significant pharmaceutical manufacturing hub, largely due to favorable tax incentives. The area hosts numerous pharmaceutical companies, benefiting from policies that encourage industrial growth. As of May 29, 2020, Himachal Pradesh had 555 pharmaceutical units, indicating a robust manufacturing presence.

While specific data on Lenalidomide production in this cluster is limited, the region's overall contribution to India's pharmaceutical output suggests potential involvement in its manufacturing.

• Diversify Supplier Base: Given that the top five exporters account for 98.9% of Lenalidomide exports, it's advisable to explore partnerships with emerging manufacturers in other clusters to mitigate supply chain risks.

• Leverage Hyderabad's API Expertise: Collaborate with manufacturers in Hyderabad for sourcing high-quality APIs, capitalizing on the region's specialization in complex drug production.

• Utilize Gujarat's Formulation Capabilities: Engage with companies in the Ahmedabad-Vadodara corridor for finished formulations, benefiting from their established infrastructure and regulatory compliance.

• Optimize Export Logistics via Maharashtra: Partner with firms in the Mumbai-Thane-Raigad belt to streamline export processes, taking advantage of the region's strategic location and export-oriented facilities.

By strategically engaging with these pharmaceutical clusters, TransData Nexus can enhance its supply chain resilience and ensure a steady supply of Lenalidomide to meet global demand.